Cargando…

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Girotti, Maria Romina, Lopes, Filipa, Preece, Natasha, Niculescu-Duvaz, Dan, Zambon, Alfonso, Davies, Lawrence, Whittaker, Steven, Saturno, Grazia, Viros, Amaya, Pedersen, Malin, Suijkerbuijk, Bart M.J.M., Menard, Delphine, McLeary, Robert, Johnson, Louise, Fish, Laura, Ejiama, Sarah, Sanchez-Laorden, Berta, Hohloch, Juliane, Carragher, Neil, Macleod, Kenneth, Ashton, Garry, Marusiak, Anna A., Fusi, Alberto, Brognard, John, Frame, Margaret, Lorigan, Paul, Marais, Richard, Springer, Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cell Press 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848950/ https://www.ncbi.nlm.nih.gov/pubmed/28292443 http://dx.doi.org/10.1016/j.ccell.2017.02.007

Ejemplares similares

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
por: Girotti, Maria Romina, et al.
Publicado: (2015)

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
por: Saturno, G., et al.
Publicado: (2021)

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
por: Marusiak, Anna A., et al.
Publicado: (2014)

Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds
por: Niculescu-Duvaz, Dan, et al.
Publicado: (2010)

Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53
por: Viros, Amaya, et al.
Publicado: (2014)

Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure–Activity Relationships
por: Leung, Leo, et al.
Publicado: (2019)

Author Correction: Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface
por: Tang, HaoRan, et al.
Publicado: (2019)

Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface
por: Tang, HaoRan, et al.
Publicado: (2017)

2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth
por: Smithen, Deborah A., et al.
Publicado: (2019)

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
por: Hirata, Eishu, et al.
Publicado: (2015)

Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation
por: Wellbrock, Claudia, et al.
Publicado: (2005)

Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma
por: Lee, Rebecca Jane, et al.
Publicado: (2020)

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA
por: Gremel, G., et al.
Publicado: (2016)

RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
por: Jin, Ting, et al.
Publicado: (2017)

Toward the Scale-Up of a Bicyclic Homopiperazine via Schmidt Rearrangement and Photochemical Oxaziridine Rearrangement in Continuous-Flow
por: Brown, Michael, et al.
Publicado: (2020)

Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients
por: Valpione, S., et al.
Publicado: (2018)

Targeting the Raf kinases in human cancer: the Raf dimer dilemma
por: Durrant, David E, et al.
Publicado: (2018)

“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
por: Cseh, Botond, et al.
Publicado: (2014)

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells
por: Spender, Lindsay C., et al.
Publicado: (2016)

Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells
por: Baenke, Franziska, et al.
Publicado: (2015)

RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
por: Poulikakos, Poulikos I., et al.
Publicado: (2010)

Molecular recognition of RAS/RAF complex at the membrane: Role of RAF cysteine-rich domain
por: Travers, Timothy, et al.
Publicado: (2018)

Somatically mutated ABL1 is an actionable and essential NSCLC survival gene
por: Testoni, Ewelina, et al.
Publicado: (2016)

Raf-1 regulates migration
por: Tuma, Rabiya S.
Publicado: (2005)

Resistance to RAF inhibitors revisited
por: Hartsough, Edward, et al.
Publicado: (2013)

Arabidopsis Raf-Like Kinase Raf10 Is a Regulatory Component of Core ABA Signaling
por: Nguyen, Quy Thi Cam, et al.
Publicado: (2019)

Crystal Structure Reveals the Full Ras–Raf Interface and Advances Mechanistic Understanding of Raf Activation
por: Cookis, Trinity, et al.
Publicado: (2021)

Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib
por: Tkacik, Emre, et al.
Publicado: (2023)

Diverse matrix metalloproteinase functions regulate cancer amoeboid migration
por: Orgaz, Jose L., et al.
Publicado: (2014)

Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
por: Bhargava, Ajay, et al.
Publicado: (2016)

A Combination of Conformation-Specific RAF Inhibitors Overcome Drug Resistance Brought about by RAF Overexpression
por: Imoto, Hiroaki, et al.
Publicado: (2023)

Molecular Modeling Unveils the Effective Interaction of B-RAF Inhibitors with Rare B-RAF Insertion Variants
por: Scaini, Maria Chiara, et al.
Publicado: (2023)

Orange is the new black: Kinases are the new master regulators of tumor suppression
por: An, Elvira, et al.
Publicado: (2018)

Mechanisms of resistance to RAF inhibitors in melanoma
por: Aplin, Andrew E., et al.
Publicado: (2011)

B-RAF unlocks axon regeneration
por: Cavalli, Valeria, et al.
Publicado: (2014)

The mechanism of Raf activation through dimerization
por: Zhang, Mingzhen, et al.
Publicado: (2021)

Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation
por: Jossé, Rozenn, et al.
Publicado: (2015)

PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation
por: Wang, Xiaojuan, et al.
Publicado: (2020)

PLX8394, a RAF inhibitor, inhibits enterovirus 71 replication by blocking RAF/MEK/ERK signaling
por: Wu, Chengyuan, et al.
Publicado: (2023)

Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells
por: Marusiak, Anna A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7rtoj9f99ie9hp15oigvlrgr8i